← All trials
NCT05752916
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- Mar 3, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 568
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Guangzhou Recomgen Biotech Co., Ltd.Collaborator
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.